Nanjing Vazyme Biotech (688105.SH) announced a pre-loss, with an estimated net loss of 20 to 12 million yuan in 2024, narrowing the loss.
Norway's praise (688105.SH) releases its 2024 annual performance forecast, with the company expecting to achieve...
Nanjing Vazyme Biotech (688105.SH) released its 2024 annual performance forecast, with the company expecting a net loss attributable to owners of the parent company of 12 to 20 million yuan, a narrowing of losses; and a net loss attributable to owners of the parent company excluding non-recurring gains and losses of 77 to 85 million yuan, also a narrowing of losses.
Related Articles
Hunan Silver (002716.SZ) director Rongqi resigns
Jiangsu Linyang Energy (601222.SH) holding shareholder Huahong Electronics plans to increase its holdings by 50-100 million yuan.
China National Nuclear Power (601985.SH): Jiangsu Lianyungang Port plans to sell 4% equity stake in China Nuclear Su Energy, while the company's ownership in China Nuclear Su Energy remains unchanged.
Hunan Silver (002716.SZ) director Rongqi resigns
Jiangsu Linyang Energy (601222.SH) holding shareholder Huahong Electronics plans to increase its holdings by 50-100 million yuan.
China National Nuclear Power (601985.SH): Jiangsu Lianyungang Port plans to sell 4% equity stake in China Nuclear Su Energy, while the company's ownership in China Nuclear Su Energy remains unchanged.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
